GENT expects CHMP decision 3Q 2012. STEM initiates Phase 1/2 AMD trial. DEPO acquires Zipsor

Jun 21, 2012 No Comments by

Gentium S.p.A. (Nasdaq:GENT)  announced today that it has submitted its responses to the Day 180 List of Outstanding Issues received from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) with respect to its Marketing Authorization Application (MAA) for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy. Gentium expects to receive an opinion from the CHMP regarding the approval of Defibrotide during 3Q 2012.

StemCells, Inc.(Nasdaq:STEM) announced it has initiated a Phase 1/2 trial of its HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD).

Depomed, Inc.(NASDAQ: DEPO) announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc.  Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.  Zipsor had approximately $19 million in sales in the 12 months ended May 31, 2012.  Depomed acquired the product in return for $25.9m of cash and potential milestone payments based on sales of Zipsor and assumption of certain liabilities.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “GENT expects CHMP decision 3Q 2012. STEM initiates Phase 1/2 AMD trial. DEPO acquires Zipsor”

Leave a Reply